Economics of antiretroviral treatment vs. circumcision for HIV prevention

• Verfasst von: Bärnighausen, Till [VerfasserIn]
• Verfasst von: Bloom, David E. [VerfasserIn]
• Verfasst von: Humair, Salal [VerfasserIn]
• Titel: Economics of antiretroviral treatment vs. circumcision for HIV prevention
• Verf.angabe: Till Bärnighausen, David E. Bloom, and Salal Humair
• E-Jahr: 2012
• Jahr: December 26, 2012
• Umfang: 6 S.
• Fussnoten: Gesehen am 30.05.2017
• Titel Quelle: Enthalten in: National Academy of Sciences (Washington, DC)Proceedings of the National Academy of Sciences of the United States of America
• Ort Quelle: Washington, DC : National Acad. of Sciences, 1915
• Jahr Quelle: 2012
• Band/Heft Quelle: 109(2012), 52, Seite 21271-21276
• ISSN Quelle: 1091-6490
• DOI: doi:10.1073/pnas.1209017110
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1559096527

Abstract

The HIV Prevention Trials Network (HPTN) 052 study, which showed the effectiveness of antiretroviral treatment in reducing HIV transmission, has been hailed as a “game changer” in the fight against HIV, prompting calls for scaling up treatment as prevention (TasP). However, it is unclear how TasP can be financed, given flat-lining support for global HIV programs. We assess whether TasP is indeed a game changer or if comparable benefits are obtainable at similar or lower cost by increasing coverage of medical male circumcision (MMC) and antiretroviral treatment (ART) at CD4 <350/μL. We develop a new mathematical model and apply it to South Africa, finding that high ART coverage combined with high MMC coverage provides approximately the same HIV incidence reduction as TasP, for